Cargando…
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
BACKGROUND: Alzheimer’s disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological endpoint. However, Alzheimer’s disease drug trials do not account for the heterogeneity of the disease in trial design, impeding...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300886/ https://www.ncbi.nlm.nih.gov/pubmed/30567585 http://dx.doi.org/10.1186/s13195-018-0455-y |